Filing Details

Accession Number:
0001181431-12-025889
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-04-26 18:23:18
Reporting Period:
2012-04-24
Filing Date:
2012-04-26
Accepted Time:
2012-04-26 18:23:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1133416 Galectin Therapeutics Inc GALT Pharmaceutical Preparations (2834) 043562325
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1522480 F John Mauldin C/O Galectin Theraputics Inc.
7 Wells Avenue, Suite 34
Newton MA 02459
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-04-24 3,847 $2.94 3,847 No 4 P Indirect By trust
Common Stock Acquisiton 2012-04-25 1,100 $3.08 4,947 No 4 P Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By trust
No 4 P Indirect By Trust
Footnotes
  1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.94 to $2.97 inclusive. The reporting person undertakes to provide Galectin Therapeutics Inc., any security holder of Galectin Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.97 to $3.08 inclusive. The reporting person undertakes to provide Galectin Therapeutics Inc., any security holder of Galectin Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. On the transaction date stated in column 2 of this row in Table I, the reporting person contributed the shares stated in column 4 of such row to a retirement fund trust of which the reporting person is a trustee and a beneficiary. The reporting person continues to report ownership of all Galectin Therapeutics common stock held by the trust but disclaims beneficial ownership except to the extent of his pecuniary interest therein.